CMB International Initiates Coverage on Haixi Pharma with 'Buy' Rating and HK$280 Target

Stock News06-10

CMB International has released a research report initiating coverage on HAIXI PHARMA (02637), assigning a 'Buy' rating and setting a target price of HK$280.

The report describes HAIXI PHARMA as an innovative, fully-integrated pharmaceutical company engaged in research, production, and sales. The company's portfolio includes 15 approved generic drugs and 4 innovative drugs in the pipeline.

A key highlight is the drug candidate HXP056, which has the potential to become the world’s first oral therapy for fundus diseases.

CMB International notes that the company's generic drug operations serve as a cash cow, providing sustained funding for its innovative research. By the end of 2025, the company is expected to have 15 approved generic drugs, with three of them holding top-two market positions, ensuring strong cash flow.

The report forecasts that the company's net profit will grow by 18.9% year-on-year to 210.5 million yuan in 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1154998341?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-10 11:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1154998341","market":"hk","top_or_hot":-1,"title":"CMB International Initiates Coverage on Haixi Pharma with 'Buy' Rating and HK$280 Target","media":"Stock News","content":"<p>CMB International has released a research report initiating coverage on <b>HAIXI PHARMA</b> (<b>02637</b>), assigning a 'Buy' rating and setting a target price of HK$280.<br><br>The report describes <b>HAIXI PHARMA</b> as an innovative, fully-integrated pharmaceutical company engaged in research, production, and sales. The company's portfolio includes 15 approved generic drugs and 4 innovative drugs in the pipeline.<br><br>A key highlight is the drug candidate HXP056, which has the potential to become the world’s first oral therapy for fundus diseases.<br><br>CMB International notes that the company's generic drug operations serve as a cash cow, providing sustained funding for its innovative research. By the end of 2025, the company is expected to have 15 approved generic drugs, with three of them holding top-two market positions, ensuring strong cash flow.<br><br>The report forecasts that the company's net profit will grow by 18.9% year-on-year to 210.5 million yuan in 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CMB International Initiates Coverage on Haixi Pharma with 'Buy' Rating and HK$280 Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCMB International Initiates Coverage on Haixi Pharma with 'Buy' Rating and HK$280 Target\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-10 11:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CMB International has released a research report initiating coverage on <b>HAIXI PHARMA</b> (<b>02637</b>), assigning a 'Buy' rating and setting a target price of HK$280.<br><br>The report describes <b>HAIXI PHARMA</b> as an innovative, fully-integrated pharmaceutical company engaged in research, production, and sales. The company's portfolio includes 15 approved generic drugs and 4 innovative drugs in the pipeline.<br><br>A key highlight is the drug candidate HXP056, which has the potential to become the world’s first oral therapy for fundus diseases.<br><br>CMB International notes that the company's generic drug operations serve as a cash cow, providing sustained funding for its innovative research. By the end of 2025, the company is expected to have 15 approved generic drugs, with three of them holding top-two market positions, ensuring strong cash flow.<br><br>The report forecasts that the company's net profit will grow by 18.9% year-on-year to 210.5 million yuan in 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1154998341","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1154998341","pubTimestamp":1781060902,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CMB International has released a research report initiating coverage on HAIXI PHARMA (02637), assigning a 'Buy' rating and setting a target price of HK$280.The report describes HAIXI PHARMA as an...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","02637":"海西新药","EWH":"香港ETF-iShares MSCI"},"translate_title":"招银国际首次覆盖海西药业给予“买入”评级目标280港元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EWH":1,"02637":1},"content_text":"CMB International has released a research report initiating coverage on HAIXI PHARMA (02637), assigning a 'Buy' rating and setting a target price of HK$280.The report describes HAIXI PHARMA as an innovative, fully-integrated pharmaceutical company engaged in research, production, and sales. The company's portfolio includes 15 approved generic drugs and 4 innovative drugs in the pipeline.A key highlight is the drug candidate HXP056, which has the potential to become the world’s first oral therapy for fundus diseases.CMB International notes that the company's generic drug operations serve as a cash cow, providing sustained funding for its innovative research. By the end of 2025, the company is expected to have 15 approved generic drugs, with three of them holding top-two market positions, ensuring strong cash flow.The report forecasts that the company's net profit will grow by 18.9% year-on-year to 210.5 million yuan in 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1154998341","isCrawlerRequest":true}